Telomir Pharmaceuticals Inc. has announced new laboratory findings showing that its investigational compound, Telomir-1, significantly reduces the survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. The data revealed a concentration-dependent decrease in cancer cell viability and mitochondrial activity, suggesting that Telomir-1 affects cellular pathways related to energy metabolism and oxidative balance. These results are consistent with previously reported effects in triple-negative breast cancer and prostate cancer models. Telomir-1's action appears to involve modulation of epigenetic and metabolic regulators, including tumor suppressor genes and iron-dependent enzymes relevant to pancreatic cancer. The company plans to expand preclinical research to additional cancer models and begin in vivo validation studies as part of its IND preparation. The company did not specify if or when these results will be presented at a scientific meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-017916), on October 14, 2025, and is solely responsible for the information contained therein.
Comments